Wilate Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved diagnosis of bleeding disorders, expansion of hemophilia treatment centers, advancements in plasma fractionation processes, increased availability of replacement therapies, growing patient awareness of prophylactic care.

The growth in the forecast period can be attributed to increasing focus on personalized bleeding disorder management, rising adoption of home infusion therapies, expansion of advanced plasma-derived products, growing investments in rare hematology treatments, increasing demand for long-term disease management solutions. Major trends in the forecast period include increasing adoption of plasma-derived therapies, rising demand for prophylactic bleeding disorder treatment, growing use of combination clotting factor products, expansion of home-based infusion models, enhanced focus on treatment safety and consistency.

The rising prevalence of bleeding disorders is expected to drive the growth of the wilate market in the coming years. Bleeding disorders occur when the blood does not clot properly, leading to prolonged or excessive bleeding. Their prevalence is influenced by genetic factors, liver disease, vitamin K deficiency, and immune system disorders. Wilate replaces missing clotting factors, such as Factor VIII or von Willebrand factor, helping to control and prevent bleeding episodes. This treatment enhances clotting ability, reduces bleeding risks, and supports healing for patients with bleeding disorders. For example, according to Pfizer Inc., a US-based biopharmaceutical corporation, in May 2025 the haemophilia A and B patient population in the UK exceeded 11,800 individuals during the 2023/2024 period. Consequently, the rising prevalence of bleeding disorders is driving the growth of the wilate market.

The increase in healthcare expenditure is also expected to support the growth of the wilate market. Healthcare expenditure encompasses spending on medical treatments, hospital care, pharmaceuticals, insurance, and public health programs. Rising expenditure is driven by an aging population, higher healthcare demands, medical advancements, chronic diseases, and expanded access to services. Increased healthcare investment improves access to advanced treatments for bleeding disorders, such as Wilate, and promotes wider adoption of innovative therapies, resulting in better patient outcomes. For instance, according to a report by the Office for National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with 0.9% growth in 2022. Therefore, rising healthcare expenditure is contributing to the growth of the wilate market.

A key trend in the wilate market is obtaining regulatory drug approvals to enhance adoption and expand its presence in treating bleeding disorders. Drug approval is the process through which authorities evaluate and authorize a new drug for sale and use, ensuring safety, efficacy, and quality based on clinical trial results. For example, in April 2024, Octapharma USA, Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted orphan drug exclusivity to Wilate, a von Willebrand factor or coagulation factor VIII complex (human) lyophilized powder for intravenous injection. This designation makes Wilate the first von Willebrand factor concentrate approved for routine prophylaxis in all types of von Willebrand disease (VWD), aiming to reduce bleeding episodes in both adults and children aged six and older. The FDA’s orphan drug status provides Wilate with up to seven years of market exclusivity, representing a significant advancement in the treatment of VWD, a condition affecting up to 1% of the U.S. population.

Major companies operating in the wilate market are Octapharma USA Inc.

North America was the largest region in the wilate market in 2025. The regions covered in the wilate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the wilate market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the wilate market by increasing costs of imported plasma-derived raw materials, fractionation equipment, sterile packaging supplies, and cold-chain logistics infrastructure. Hematology clinics and hospitals in North America and Europe are most affected due to reliance on international plasma sourcing and specialized manufacturing inputs, while Asia-Pacific faces higher costs in expanding plasma therapy access. These tariffs are raising treatment costs and operational complexity for providers. However, they are also encouraging regional plasma collection programs, domestic fractionation investments, and stronger localized supply chains for bleeding disorder therapies.

The wilate market research report is one of a series of new reports that provides wilate market statistics, including wilate industry global market size, regional shares, competitors with a wilate market share, detailed wilate market segments, market trends and opportunities, and any further data you may need to thrive in the wilate industry. This wilate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Wilate is a medication used to manage or prevent bleeding episodes in individuals with certain bleeding disorders, including von Willebrand disease (VWD) and hemophilia A. It supplies von Willebrand factor (VWF) and factor VIII, both essential for proper blood clotting.

The primary indications for Wilate are hemophilia A and von Willebrand disease (VWD). Hemophilia A is a hereditary disorder caused by a deficiency of clotting factor VIII, leading to impaired blood clotting and an increased risk of bleeding. Wilate is distributed through hospitals and clinics, retail pharmacies, and online pharmacies, and is used by various patient groups, including adults and elderly patients.

The wilate market consists of sales of vials, associated administration kits, infusion sets, and sterile syringes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.